Vitamin Shoppe estimates and price target raised at JPMorgan JPMorgan believes Vitamin Shoppe's acceleration in footage growth and improvements in merchandising has made the company's story more compelling. The firm raised its 2013 earnings estimates above consensus and upped its price target for shares to $73 from $69 while keeping an Overweight rating on the stock.
News For VSI From The Last 14 Days
Check below for free stories on VSI the last two weeks.
Vitamin Shoppe comps should should show acceleration, says RW Baird Baird expects Q2 earnings at Vitamin Shoppe to be in-line but believes its comparable sales should show an acceleration and an improved margin performance relative to prior quarters. The firm also believes concerns over increased promotional activity are overblown. Baird likes the stock at current levels and keeps a Buy rating with a $55 price target on the shares.
Vitamin Shoppe recommended ahead of Q2 report at Goldman Goldman believes Vitamin Shoppe (VSI) competitive pressures are overblown and that the company has relatively low overlap with GNC (GNC) and that recent price cuts have had minimal impact. The firm expects Vitamin Shoppe's Q2 to mark the beginning of sharp earnings acceleration and better execution and recommends buying shares ahead of the Q2 report. Shares are rated Conviction Buy with a $60 price target.